Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Revenue of Achieve Life Sciences, Inc. (ACHV)
Revenue in 2023 (TTM): $
According to Achieve Life Sciences, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Achieve Life Sciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-228,000 | $-26,734,000 | $-29,815,000 | $-29,815,000 |
| 2022 | $ | $-236,000 | $-40,325,000 | $-42,350,000 | $-41,875,000 |
| 2021 | $ | $-250,000 | $-32,902,000 | $-33,152,000 | $-32,902,000 |
| 2020 | $ | $-255,000 | $-14,475,000 | $-14,730,000 | $-14,661,000 |
| 2019 | $ | $-254,000 | $-16,140,999 | $-16,395,000 | $-16,141,000 |
| 2018 | $ | $-282,000 | $-12,405,000 | $-12,687,000 | $-12,687,000 |
| 2017 | $ | $-282,000 | $-13,352,000 | $-13,634,000 | $-10,583,000 |
| 2016 | $5.06 M | $5.06 M | $-19,941,000 | $-20,129,000 | $-20,129,000 |
| 2015 | $18.16 M | $18.16 M | $-16,557,000 | $-16,801,000 | $-16,801,000 |
| 2014 | $27.12 M | $27.12 M | $-26,017,000 | $-26,240,000 | $-26,240,000 |
| 2013 | $29.88 M | $29.88 M | $-31,622,000 | $-31,849,000 | $-31,849,000 |
| 2012 | $20.1 M | $20.1 M | $-20,998,000 | $-21,098,000 | $-21,098,000 |
| 2011 | $5.5 M | $5.5 M | $-22,212,000 | $-14,673,000 | $-14,673,000 |
| 2010 | $13.62 M | $13.62 M | $-15,532,000 | $-15,584,000 | $-12,584,000 |
| 2009 | $25.54 M | $25.54 M | $1.42 M | $2.47 M | $5.48 M |
| 2008 | $20.13 M | $20.13 M | $-10,602,000 | $-10,691,000 | $-4,204,000 |
| 2007 | $20.13 M | $20.13 M | $-12,407,044 | $-15,360,303 | $-13,063,168 |
| 2006 | $22.39 M | $22.39 M | $-22,938,697 | $-26,399,184 | $-23,551,296 |
| 2005 | $8.25 M | $8.25 M | $-20,497,368 | $-21,805,059 | $-21,097,017 |
| 2004 | $264.96 M | $264.96 M | $-15,733,690 | $-16,310,592 | $-16,310,592 |
| 2003 | $25 K | $25 K | $-10,257,725 | $-10,467,099 | $-10,467,099 |
| 2002 | $25 K | $25 K | $-11,593,478 | $-11,737,284 | $-11,635,801 |
| 2001 | $8.75 M | $3.53 M | $474.45 K | $742.18 K | $542.18 K |
| 2000 | $408.41 K | $-3,281,593 | $-6,875,204 | $-2,324,376 | $-2,147,437 |
| 1999 | $12.1 M | $12.7 M | $589.54 K | $430 K | $400 K |
| 1998 | $5.1 M | $5.9 M | $-11,081,218 | $-11,170,000 | $-11,200,000 |
| 1997 | $18.9 M | $19.5 M | $700 K | $1.1 M | $1000 K |
| 1996 | $16.6 M | $17.1 M | $2.1 M | $2.2 M | $1.7 M |
| 1995 | $4.5 M | $4.8 M | $-4,600,000 | $-5,400,000 | $-5,900,000 |
| 1994 | $1.1 M | $-4,400,000 | $-7,900,000 | $-8,700,000 | $-8,900,000 |